

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/H18DD5423B4EN.html>

Date: March 2018

Pages: 138

Price: US\$ 3,500.00 (Single User License)

ID: H18DD5423B4EN

Abstracts

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018

SUMMARY

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 29 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 4, 6, 12 and 2 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Follicular Lymphoma, Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Melanoma, Myelodysplastic Syndrome, Neuroblastoma, Relapsed Acute Myeloid

Leukemia, Thalassemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Colon Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Liver Cancer, Mantle Cell Lymphoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Sickle Cell Disease, Solid Tumor, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Colorectal Cancer, Depression, Duchenne Muscular Dystrophy, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Neuroendocrine Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sezary Syndrome, Skin Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Systemic Lupus Erythematosus and Thyroid Cancer.

The latest report Histone Deacetylase 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor

presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Overview

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development

4SC AG

AlfaSigma SpA

Celgene Corp

Chipscreen Biosciences Ltd

Curis Inc

HitGen LTD

IRBM Science Park SpA

Italfarmaco SpA

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Mirati Therapeutics Inc

Syndax Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles

4SC-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACY-1035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress
ACY-1071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-738 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-957 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crocetin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-3158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
largazole - Drug Profile
Product Description

Mechanism Of Action

R&D Progress

mocetinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pracinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RCY-1305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RCY-1497 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RCY-1992 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remetinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resminostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit KDM1A, HDAC1 and HDAC2 for Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit HDAC1 and 2 for Acute Myeloid Leukemia and
Myelodysplastic Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-3595 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tucidinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vorinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued Products

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development Milestones

Featured News & Press Releases

Feb 07, 2018: University of Colorado: Treatment for Diastolic Dysfunction

Jan 31, 2018: Positive DSMB safety review of 4SC's pivotal RESMAIN study of

resminostat in CTCL

Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

Jan 10, 2018: Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer

Dec 20, 2017: 4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency

Dec 13, 2017: 4SC receives milestone payment from Immunic

Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting

Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition

Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting

Nov 07, 2017: Syndax to Present Data On Entinostat at SITC 32nd Annual Scientific Meeting

Oct 13, 2017: Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL

Oct 12, 2017: Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients

Oct 10, 2017: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients

Oct 05, 2017: Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by 4SC AG, H1 2018
Pipeline by AlfaSigma SpA, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Chipscreen Biosciences Ltd, H1 2018
Pipeline by Curis Inc, H1 2018
Pipeline by HitGen LTD, H1 2018
Pipeline by IRBM Science Park SpA, H1 2018
Pipeline by Italfarmaco SpA, H1 2018
Pipeline by Medivir AB, H1 2018
Pipeline by MEI Pharma Inc, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Mirati Therapeutics Inc, H1 2018
Pipeline by Syndax Pharmaceuticals Inc, H1 2018
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Dormant Products, H1 2018 (Contd..3), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

4SC AG

AlfaSigma SpA

Celgene Corp

Chipscreen Biosciences Ltd

Curis Inc

HitGen LTD

IRBM Science Park SpA

Italfarmaco SpA

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Mirati Therapeutics Inc

Syndax Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

I would like to order

Product name: Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/H18DD5423B4EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H18DD5423B4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970